American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunology of endometrial cancers: Tumor genetics, immune recognition, and immunotherapy response
    Meeting Abstract

    Zamarin, D.
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) outcomes in arandomized controlled trial of yoga in breast and gynecological cancer survivors with chemotherapy-induced peripheral neuropathy
    Meeting Abstract

    Zhi, W. I.; Baser, R.; Zhi, L.; Piulson, L.; Li, Q.; Bao, T.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Global proteomic profiling of endometrial carcinomas identify prognostic markers
    Meeting Abstract

    Cochrane, D. R.; Negri, G.; Huvila, J.; Farnell, D. A.; Thompson, E.; Yang, W.; Trigo-Gonzales, G.; Lum, A.; Spencer, S.; Riley, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Identification of proteomics-based biomarkers for ER+/HER2- breast cancer stratification: Implications on clinical outcome
    Meeting Abstract

    Wang, G.; Shah, P.; Searfoss, R.; Campbell, J. L. F.; Hooke, J. A.; Deyarmin, B.; Zingmark, R. N.; Somiari, S.; Liu, J.; Kvecher, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Meeting Abstract

    Rugo, H. S.; Lerebours, F.; Juric, D.; Turner, N.; Chia, S.; Drullinsky, P.; Prat, A.; Vázquez, R. V.; Akdere, M.; Arce, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Inflammation and coagulation biomarkers associated with physical resilience in older women receiving chemotherapy for early breast cancer
    Meeting Abstract

    Sedrak, M. S.; Sun, C.; Muss, H.; Freedman, R. A.; Magnuson, A.; Gross, C. P.; Tew, W. P.; Klepin, H. D.; Wildes, T. M.; Dotan, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Outcomes for metaplastic breast cancer differ by histologic subtype
    Meeting Abstract

    Tadros, A. B.; Sevilimedu, V.; Zabor, E.; Giri, D.; Morrow, M.; Plitas, G.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
    Meeting Abstract

    O'Shaughnessy, J.; Schwartzberg, L.; Piccart, M.; Rugo, H. S.; Yardley, D. A.; Cortes, J.; Untch, M.; Harbeck, N.; Wright, G. S.; Bondarenko, I.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: